Navigation Links
Transgenomic Reports First Quarter Financial Results
Date:5/12/2011

for the company. "When we completed our acquisition of the FAMILION business, we were challenged as a new corporate team to bring together two businesses that were losing a combined $7.5 million a year just prior to completing the acquisition. Our goals were to improve operating margins immediately, complete the integration of our two CLIA-certified reference labs into a single lab operation and demonstrate significant improvement quickly.  In our first combined quarter, we are on track to meet all of these expectations.  In the second quarter, we will complete the final components of integrating our laboratories.  We also expect improvement in our Neurology testing business by expanding coverage under the managed care contracts which we secured with the Familion transaction. We are also very pleased with our customer retention efforts through the lab integration activities. All of our customer relationship efforts have proven effective.  Despite a soft start to the year in lab tests ordered during the Christmas holiday season, we have seen test request volume return to its previous level during the quarter."

"We are also excited to see the increase in testing volume in our Pharmacogenomics Services business," Tuttle further commented. "We have increased the total number of projects being performed, increased our project pipeline and our total number of new contracted projects. This will continue to fuel growth in our Pharma services business both due to our expertise in mutation profiling for cancer drug trials and data for FDA submission as well as for new projects employing our Ice COLD-PCR and recently discovered BLOCker-Sequencing technologies."

Transgenomic anticipates growth in both our diagnostics and our laboratory services businesses as we commercialize new assay technologies and tests we have developed internally or in-licensed to expand our menu. In particular, we have substantially increased our footprint in the molecu
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
2. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
3. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
4. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
5. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
6. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
7. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
8. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
9. Transgenomic Reports Fourth Quarter Financial Results
10. Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010
11. Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... CHICAGO, Ill., July 25, 2014 NOT ... DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE ... LAWS OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ... ended June 30, 2014. "This was another ... earnings per share above our original guidance and announced plans ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals ... compounds that will be added to Parnell,s already ... CIMTECH Pty Ltd, a biotechnology company. The compounds ... have shown promise in bone regeneration and dermal ... develop the compounds for the veterinary market with ...
(Date:7/24/2014)... Germany , and MARSEILLE, France ... , Exclusive global license from University of Tokyo ... next-generation sequencing (NGS) gene panels, for blood cancers  ... new test, indicate favorable prognosis for patients with bone ... sees potential for developing companion diagnostics to guide treatment ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... First Patient Dosed in Phase 1 Trial of SBI-087, Trubion,s Next-Generation ... ... April 21 Trubion Pharmaceuticals,Inc. (Nasdaq: TRBN ) today announced ... WYE ), has initiated a Phase 1,clinical trial of SBI-087, a ...
... 21 Nostrum, a privately-held,company based in ... has,successfully completed its early, primate, proof-of-concept study ... as SMRX11. Nostrum,s,Symmetrix subsidiary, based in Singapore, ... license from the Institute of Microbial,Technology, Chandigarh, ...
Cached Medicine Technology:Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis 4Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein 2
(Date:7/25/2014)... Ticket Down is a reliable source for ... at California Memorial Stadium. With the post-World Cup emotions ... organizers of the 2014 Guinness International Champions Cup have brought ... With teams representing La Liga, English Premier League, Serie A, ... best football players from around the world to 12 American ...
(Date:7/25/2014)... Port Washington, NY (PRWEB) July 25, 2014 ... to protecting the rights of consumers comments on a ... the widow of a smoker $23.6 billion in punitive ... which manufactures Kool brand cigarettes. The case is Cynthia ... in 2008 in the Florida First Circuit Court, Escambia ...
(Date:7/25/2014)... study involving nearly 27,000 older adults on five continents ... pre-dementia based on a simple test that measures how ... People who tested positive for pre-dementia were twice as ... The study, led by scientists at Albert Einstein ... Montefiore Medical Center , was published online on July ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Hastings and ... offering discount attorney’s fees with regard to personal injury ... provide a wide range of legal services for those ... negligence of another individual or corporation. Free initial consultation ... the validity of a potential personal injury claim ...
(Date:7/25/2014)... York (PRWEB) July 25, 2014 As ... forward in U.S. courts, Bernstein Liebhard LLP notes that ... petition by the consumer advocacy group, Public Citizen, to ... In a letter dated May 1, 2014, and released ... the group’s petition for a ban on the marketing ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Slow walking speed and memory complaints can predict dementia 2Health News:Slow walking speed and memory complaints can predict dementia 3Health News:Slow walking speed and memory complaints can predict dementia 4Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: FDA Rejects Petition Seeking Ban and Global Recall of All Transvaginal Mesh Products, Bernstein Liebhard LLP Reports 4
... Jan. 11, 2010 Amerigroup Corporation (NYSE: AGP ) ... quarter and the fiscal year ended December 31, 2009, at approximately ... 8:30 a.m. Eastern Time on the same day, Amerigroup,s management will ... information. , To listen to the call, dial 866-260-3161 (domestic) or ...
... Mass., Jan. 11 ( http://www.myprgenie.com ) -- Panel Intelligence, ... name back to MedPanel, LLC ("MedPanel"), the company,s original name ... name has been restored to reflect the company,s renewed, singular ... 2009. , "We are excited and proud to be independent ...
... could be used to guide treatment, researchers suggest , MONDAY, ... entire human genome has found a genetic variant associated with ... an important first step toward singling out cancers that need ... , "It is a proof of principle to show that ...
... , SC AG McMaster to Address ... , WASHINGTON, Jan. 11 South Carolina Attorney General ... into the constitutionality of the health care reform bill being ... press conference at 2:00 p.m. on Wednesday, January 13th, in ...
... WebMD Health Corp. (Nasdaq: WBMD ) today announced that executives ... Growth Stock Conference on Thursday, January 14, 2010 at 11:20 a.m. ... invited to listen to a live audio broadcast of the presentation ... www.wbmd.com (in the Investor Relations section). A replay of the ...
... Wake Forest University Baptist Medical Center and colleagues have ... cancer, proving the concept that genetic information may one ... guide treatment decisions. The research will be reported ... of the National Academy of Sciences . "This ...
Cached Medicine News:Health News:Amerigroup Corporation to Discuss Fourth Quarter and 2009 Year-End Earnings on February 19 2Health News:Panel Intelligence Returns to MedPanel Name 2Health News:Genetic Marker for Aggressive Prostate Cancer Found 2Health News:Genetic Marker for Aggressive Prostate Cancer Found 3Health News:Genetic variant associated with aggressive form of prostate cancer 2
MISTY OX® Gas Injection Nebulizer (GIN)...
... The Raindrop® medication nebulizer achieves optimum lung ... particle size range is 1.04-1.10 µ at ... or air outlet., ,As the world ... healthcare providers the assurance of proven technology ...
... for makeshift, modified nebulizer setups to deliver ... parts when your patient is critical? OMNI~MAX ... utmost in Heliox rescue therapy. In severe ... the standard of care in hospitals across ...
... World's smallest nebulizer utilizing Vibrating Mesh ... for patients suffering from Asthma, COPD ... the small product size and handy ... wherever life takes them. Powerful delivery ...
Medicine Products: